Antitumor activity of CDA‑Ⅱ, a urinary preparation, on human multiple myeloma cell lines via the mitochondrial pathway

Yang,Min; Huang,Jian; Ma,Qiu‑Ling; Xu,Gai‑Xiang; Jin,Jie

doi:10.3892/mmr.2014.1911

Antitumor activity of CDA‑Ⅱ, a urinary preparation, on human multiple myeloma cell lines via the mitochondrial pathway

Authors:
- Min Yang
- Jian Huang
- Qiu‑Ling Ma
- Gai‑Xiang Xu
- Jie Jin
View Affiliations

Affiliations: Department of Hematology, Institute of Hematology, The First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, P.R. China
Published online on: January 22, 2014 https://doi.org/10.3892/mmr.2014.1911
Pages: 1025-1031

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cell differentiation agent II (CDA‑II) is a DNA methyltransferase inhibitor isolated from healthy human urine. In the present study, the antitumor activity of CDA‑II on human multiple myeloma (MM) cell lines via the mitochondrial pathway was first revealed. The human MM cell lines were exposed to CDA‑II. Cytotoxicity, caspase activation, apoptosis and the effects on the mitochondrial pathway were assessed. CDA‑Ⅱ was capable of decreasing the depolarized mitochondrial membranes and activating caspase‑3 and ‑9 and poly (ADP‑ribose) polymerase in MM cells treated with CDA‑II. CDA‑II induced caspase‑dependent cell death accompanied by a significant decrease in X-linked inhibitor of apoptosis protein (XIAP), survivin and Mcl‑1 levels. The caspase‑3 inhibitor, Z‑DEVD‑FMK, inhibited CDA‑II‑induced apoptosis. CDA‑II potently increased the Bax levels, decreased the Bcl‑2/Bax ratio and decreased the expression of the downstream targets of NF‑κB. In conclusion, the results of the present study demonstrated that CDA‑II treatment leads to the inhibition of p65 nuclear localization and potently induces caspase‑dependent apoptosis in MM cells mediated through the mitochondrial pathway at low nanomolar concentrations. These results indicate that CDA‑II is a novel inhibitor of NF‑κB activity, with notable antimyeloma efficacy. This study provides a rationale for the clinical investigation of CDA‑Ⅱ in human MM.

View Figures

View References

1	Gregory WM, Richards MA and Malpas JS: Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol. 10:334–342. 1992.PubMed/NCBI
2	Lenhoff S, Hjorth M, Holmberg E, et al: Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood. 95:7–11. 2000.PubMed/NCBI
3	Attal M, Harousseau JL, Facon T, et al; InterGroupe Francophone du Myélome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 349:2495–2502. 2003. View Article : Google Scholar : PubMed/NCBI
4	Sonneveld P: Drug resistance in multiple myeloma. Pathol Biol (Paris). 47:182–187. 1999.PubMed/NCBI
5	Covelli A: Modulation of multidrug resistance (MDR) in hematological malignancies. Ann Oncol. 10(Suppl 6): 53–59. 1999. View Article : Google Scholar : PubMed/NCBI
6	Schwarzenbach H: Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med Oncol. 19:87–104. 2002. View Article : Google Scholar : PubMed/NCBI
7	Burzynski SR: Antineoplastons: history of the research (I). Drugs Exp Clin Res. 12(Suppl 1): 1–9. 1986.
8	Badria F, Mabed M, Khafagy W and Abou-Zeid L: Potential utility of antineoplaston A-10 levels in breast cancer. Cancer Lett. 155:67–70. 2000. View Article : Google Scholar : PubMed/NCBI
9	Lin WC, Wu YW, Lai TY and Liau MC: Effect of CDA-II, urinary preparation, on lipofuscin, lipid peroxidation and antioxidant systems in young and middle-aged rat brain. Am J Chin Med. 29:91–99. 2001. View Article : Google Scholar : PubMed/NCBI
10	Masood R, McGarvey ME, Zheng T, Cai J, Arora N, Smith DL, Sloane N and Gill PS: Antineoplastic urinary protein inhibits Kaposi’s sarcoma and angiogenesis in vitro and in vivo. Blood. 93:1038–1044. 1999.
11	Yao CJ, Lai GM, Chan CF, Yang YY, Liu FC and Chuang SE: Differentiation of pheochromocytoma PC12 cells induced by human urine extract and the involvement of the extracellular signal-regulated kinase signaling pathway. J Altern Complement Med. 11:903–908. 2005. View Article : Google Scholar : PubMed/NCBI
12	Liau MC, Szopa M, Burzynski B and Burzynski SR: Quantitative assay of plasma and urinary peptides as an aid for the evaluation of cancer patients undergoing antineoplaston therapy. Drugs Exp Clin Res. 13(Suppl 1): 61–70. 1987.PubMed/NCBI
13	Sun JJ, Zhou Xd and Liu YK: Effect of CDA-II on prevention and therapy for metastasis and recurrence of liver cancer in nude mice. Chin J Hepatobiliary Surg. 546–551. 2006.(In Chinese).
14	Sun L, Huang Q, Wang A, Lan Q, Du Z and Hu G: cDNA array in the establishment of a gene expression profile associated with differentiation inducing the glioma cells. Zhonghua Zhong Liu Za Zhi. 24:222–225. 2002.(In Chinese).
15	Wang YH and Zheng WI: Effects of uroacitides on proliferation ability of breast cancer cells. Chinese Journal of Clinical Pharmacology and Therapeutics. 10:677–681. 1999.(In Chinese).
16	Lin WC, Liao YC, Liau MC, Lii CK and Sheen LY: Inhibitory effect of CDA-II, a urinary preparation, on aflatoxin B(1)-induced oxidative stress and DNA damage in primary cultured rat hepatocytes. Food Chem Toxicol. 44:546–551. 2006. View Article : Google Scholar : PubMed/NCBI
17	Chen Z, Jin G, Lin S, Lin X, Gu Y, Zhu Y, Hu C, Zhang Q, Wu L and Shen H: DNA methyltransferase inhibitor CDA-II inhibits myogenic differentiation. Biochem Biophys Res Commun. 422:522–526. 2012. View Article : Google Scholar : PubMed/NCBI
18	Huang J, Yang M, Liu H and Jin J: Human urine extract CDA-2 induces apoptosis of myelodysplastic syndrome-derived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner. Acta Pharmacol Sin. 29:951–964. 2008. View Article : Google Scholar : PubMed/NCBI
19	Fischer U and Schulze-Osthoff K: Apoptosis-based therapies and drug targets. Cell Death Differ. 12(Suppl 1): 942–961. 2005. View Article : Google Scholar
20	Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, Evans RL and Andreeff M: Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood. 108:630–637. 2006. View Article : Google Scholar : PubMed/NCBI
21	Burzynski SR: The present state of antineoplaston research (1). Integr Cancer Ther. 3:47–58. 2004. View Article : Google Scholar : PubMed/NCBI
22	Hehir KM, Baguisi A, Pennington SE, Bates JM and DiTullio PA: A potential antitumor peptide therapeutic derived from antineoplastic urinary protein. Peptides. 25:543–549. 2004. View Article : Google Scholar : PubMed/NCBI
23	Lakhani NJ, Sparreboom A, Xu X, Veenstra TD, Venitz J, Dahut WL and Figg WD: Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol. J Pharm Sci. 96:1821–1831. 2007. View Article : Google Scholar : PubMed/NCBI
24	Linder-Stragliotto C, Strander H, Munck-Wikland E and Sten-Linder M: Low levels of endostatin in the urine from patients with malignant disease. Tumour Biol. 23:222–227. 2002. View Article : Google Scholar : PubMed/NCBI
25	Huang J, Yang M, Liu H and Jin J: CDA-II, a urinary preparation, induces growth arrest and apoptosis of human leukemia cells through inactivation of nuclear factor-kappaB in a caspase-dependent manner. Food Chem Toxicol. 47:40–49. 2009. View Article : Google Scholar
26	Zhang B, Gojo I and Fenton RG: Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood. 99:1885–1893. 2002. View Article : Google Scholar : PubMed/NCBI
27	Tu Y, Renner S, Xu F, et al: BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res. 58:256–262. 1998.PubMed/NCBI
28	Bharti AC, Shishodia S, Reuben JM, et al: Nuclear factor-kappaB and STAT3 are constitutively active in CD138⁺ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood. 103:3175–3184. 2004.PubMed/NCBI
29	Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, Bataille R and Amiot M: Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res. 67:5418–5424. 2007. View Article : Google Scholar : PubMed/NCBI
30	Han J, Goldstein LA, Gastman BR and Rabinowich H: Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem. 281:10153–10163. 2006. View Article : Google Scholar : PubMed/NCBI
31	Podar K, Gouill SL, Zhang J, Opferman JT, Zorn E, Tai YT, Hideshima T, Amiot M, Chauhan D, Harousseau JL and Anderson KC: A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Oncogene. 27:721–731. 2008. View Article : Google Scholar : PubMed/NCBI
32	Nakagawa Y, Abe S, Kurata M, Hasegawa M, Yamamoto K, Inoue M, Takemura T, Suzuki K and Kitagawa M: IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol. 81:824–831. 2006. View Article : Google Scholar
33	Spets H, Strömberg T, Georgii-Hemming P, Siljason J, Nilsson K and Jernberg-Wiklund H: Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6(IL-6)-induced growth and survival. Eur J Haematol. 69:76–89. 2002. View Article : Google Scholar : PubMed/NCBI